Dyadic International : Presentation | MarketScreener

Dyadic International (NASDAQ: DYAI) Next Generation Proteins for World Health

C1 Vaccine Technology Presentation

Mark Emalfarb, Founder & CEO

Vaccine Technology Summit

September 15-16, 2022

London UK

Safe Harbor Regarding Forward-looking Statements

Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic’s expectations, intentions, strategies and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors, including those described in Dyadic’s most recent filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this presentation, which are based on information available to us on the date hereof. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com

Dyadic’s Mission: Greater Quantities of Lower Cost Proteins for World Health

Meeting the growing demand for proteins worldwide for human and animal health with highly productive scalable microbial biomanufacturing platforms.

To improve how we feed, fuel, and heal the world by utilizing modern biotechnology to revolutionize science, medicine, agriculture, nutrition and food.

Mark Emalfarb

Founder, CEO

Proven entrepreneur, inventor 25+ U.S. and foreign biotechnology patents, filamentous fungal enzyme product commercialization

Over $100MM and 30 Years of Commercial Engineering Invested in C1

“C1” (Thermothelomyces heterothallica) is an exceptional genetically engineered fungal strain

Broad application of C1 has expanded through decades of commercial engineering

C1 strain discovered to produce commercially valuable enzymes

Commercial launch of C1 enzymes produced for industrial textile manufacturing

C1 molecular toolkit optimized for broad development across other industries including human therapeutic applications

Genome sequenced and cell line refined for high purity in industrial manufacturing

Enzyme library developed

C1 launched in biofuels industry

Generally Recognized as Safe (GRAS) designation by FDA

Launch of human biologics development for vaccines and biosimilars

Proof-of-Concept collaborations with pharma industry accelerate

Global partnerships and R&D projects with top pharma and leading animal health companies

Preparations for 1st in human trials: DYAI- 100 COVID Vaccine moving into in Phase 1 Clinical Trial in South Africa & India

C1 produced COVID-19 mAb shows safety and efficacy in hamsters and nonhuman primate studies

Strategic partnerships and collaborations:

  • Janssen
  • Rubic
  • Epygen
  • Syngene

C1 Protein Production Capability has Key Advantages vs. Other Platforms

Potential to disrupt conventional manufacturing platforms by overcoming key production limitations






  • High retention of target secreted protein through downstream processing
  • No requirement for viral (i.e., CHO) or endotoxin ( i.e., E.coli) inactivation
  • Robust & versatile growth conditions
  • High yields of secreted protein
  • Low viscosity due to C1’s unique morphology
  • Broad commercial scale size, ranging from laboratory microtiter plates, shake flasks, single use and/or stainless-steel microbial bioreactors.
  • Stable and correctly folded mAbs; Binding and neutralizing properties similar to CHO cells
  • Develop stable C1 cell lines in ~ 7 weeks
  • Production time savings of ~30 days over CHO-cell production (C1: 12-14days vs CHO: 41-54days)
  • Potential to make ~ 3-4 batches of mAbs in the same time it takes to make 1 batch using CHO cells
  • High yields and rapid production cycle times reduce cost and shrink manufacturing footprint
  • Requires only low-cost cGMP synthetic media; C1 media <1/20 of the cost of CHO media
  • No requirement for viral or endotoxin inactivation, simplifies processing compared to CHO & E.coli saving time, money

This is an excerpt of the original content. To continue reading it, access the original document here.


Dyadic International Inc. published this content on 16 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 September 2022 15:09:05 UTC.

Publicnow 2022


Analyst Recommendations on DYADIC INTERNATIONAL, INC.

Sales 2022 6,55 M

Net income 2022 -10,4 M

Net Debt 2022

P/E ratio 2022 -5,86x
Yield 2022
Capitalization 59,1 M
59,1 M
Capi. / Sales 2022 9,03x
Capi. / Sales 2023 6,00x
Nbr of Employees 7
Free-Float 49,3%


Duration :

Period :

Dyadic International, Inc. Technical Analysis Chart | MarketScreener

Technical analysis trends DYADIC INTERNATIONAL, INC.

Short Term Mid-Term Long Term
Trends Bearish Neutral Neutral

Income Statement Evolution



Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 2,08 $
Average target price 7,50 $
Spread / Average Target 261%

Read more here: Source link